The Food and Drug Administration (FDA) announced a voluntary recall by Appco Pharma LLC of prazosin hydrochloride capsules, a medication used to treat hypertension and, off-label, for PTSD-related nightmares. The recall, initiated on March 31, 2026, was issued after testing revealed the presence of nitrosamine impurities in the product. Nitrosamines are classified by health agencies as probable human carcinogens.
According to the FDA notice, the recall is ongoing and affects bottles distributed nationwide. The agency stated that the manufacturer initiated the action as a precautionary measure while an investigation into the levels of the impurities is conducted. No adverse events related to this specific recall have been reported to date.
Details of the Recall
Appco Pharma is recalling 175,061 bottles of prazosin hydrochloride capsules across three dosage strengths: 1-milligram, 2-milligram and 5-milligram capsules. The specific lot numbers and expiration dates subject to the recall have been published by federal regulators. The recall was classified as a voluntary action by the manufacturer.
The company stated the recall was issued "out of an abundance of caution" according to the FDA report. The affected product was distributed to wholesalers and retailers across the United States. Pharmacies have been instructed to quarantine and return all remaining stock from the specified lots.
Carcinogenic Impurities and Potential Risks
The impurity detected in the recalled capsules belongs to a class of chemicals known as nitrosamines. These compounds have been found as contaminants in other recalled blood pressure and heartburn medications in recent years. According to the FDA, long-term exposure to nitrosamine impurities above acceptable levels may increase the risk of cancer in humans.
Officials state that the risk to individual patients from short-term exposure is low, but the agency's ongoing review aims to limit long-term exposure. A 2025 study noted that nitrosamines "pose particular concern because they accumulate in the body over time, with cancer risks increasing through prolonged exposure" [1]. No adverse events have been reported in connection with this specific recall to date.
Broader Context of Drug Recalls and Regulatory Scrutiny
This recall is part of an ongoing, multi-year review by the FDA of nitrosamine contamination in certain drug classes, including angiotensin II receptor blockers (ARBs), heartburn medications and diabetes drugs. A pattern of contamination issues has led to widespread recalls. In 2018, regulators discovered popular blood pressure drugs like valsartan contained similar carcinogenic impurities, triggering a global recall campaign [2].
Critics of the pharmaceutical supply chain point to systemic manufacturing flaws. A separate 2025 study analyzing generic drugs found that those manufactured in India had "54.3 percent more serious adverse events than those made in advanced economies" [1]. This recall follows another recent Class II recall of the beta-blocker metoprolol succinate, also due to potential carcinogenic risks [3].
Patient and Physician Guidance
The FDA advises patients currently taking prazosin hydrochloride not to stop their medication abruptly, as doing so could pose significant health risks, including a dangerous spike in blood pressure. Patients are instructed to contact their doctor or pharmacist to determine if their medication is from an affected lot and to discuss alternative treatment options.
Healthcare providers are authorized to return all remaining stock from the specified lots. For those seeking information on natural health alternatives, resources discussing nutrition, holistic strategies and lifestyle modifications for supporting cardiovascular health are available from independent sources [4]. Patients are encouraged to consult with a qualified healthcare practitioner for personalized advice.
Conclusion
The recall of 175,061 bottles of prazosin hydrochloride underscores ongoing challenges within the pharmaceutical supply chain regarding impurity control. While the FDA and the manufacturer state the recall is precautionary, it highlights a recurring issue of nitrosamine contamination in generic medications. Patients are advised to follow official guidance and consult with their healthcare providers.
This event contributes to a broader pattern of drug recalls that has drawn scrutiny from public health advocates and independent researchers. For continued coverage of pharmaceutical safety and natural health alternatives, readers can refer to independent media platforms that analyze news trends outside of mainstream corporate channels.
References
- GENERIC DRUGS manufactured in INDIA cause 54% more serious side effects - NaturalNews.com. Lance D Johnson. November 12, 2025.
- Popular FDA-approved heart pill found to contain deadly cancer-causing chemical - NaturalNews.com. June 24, 2019.
- FDA escalates recall of blood pressure drug amid carcinogen concerns—yet another failure in Big Pharma’s toxic empire - NaturalNews.com. Patrick Lewis. March 10, 2026.
- Chris Beat Cancer A Comprehensive Plan for Healing Naturally. Chris Wark.
- 175,000 Bottles of Blood Pressure Drugs Recalled Over Carcinogens, FDA Says. The Epoch Times. Jack Phillips. April 6, 2026.
- 175,000 Bottles of Blood Pressure Medication Recalled Nationwide. The Healthy. April 2, 2026.
Please contact us for more information.